New hope for nigerians with colorectal cancer: immunotherapy trial launches

NCT ID NCT06529523

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests whether the drug tislelizumab can shrink tumors in 40 people with colorectal cancer in Nigeria. Participants have a specific type of cancer (mismatch repair deficient) and have not received any prior treatment. The goal is to see if the drug is effective and safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Lagos University Teaching Hospital
NOT_YET_RECRUITING

Idi-Araba, Lagos, Nigeria

Contact Phone: •••-•••-••••
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-••••
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITING

Ile-Ife, Nigeria

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

COLORECTAL CANCER